Hélène Karcher

1.1k total citations
44 papers, 709 citations indexed

About

Hélène Karcher is a scholar working on Ophthalmology, Radiology, Nuclear Medicine and Imaging and Economics and Econometrics. According to data from OpenAlex, Hélène Karcher has authored 44 papers receiving a total of 709 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Ophthalmology, 14 papers in Radiology, Nuclear Medicine and Imaging and 12 papers in Economics and Econometrics. Recurrent topics in Hélène Karcher's work include Retinal Diseases and Treatments (15 papers), Retinal Imaging and Analysis (13 papers) and Retinal and Optic Conditions (12 papers). Hélène Karcher is often cited by papers focused on Retinal Diseases and Treatments (15 papers), Retinal Imaging and Analysis (13 papers) and Retinal and Optic Conditions (12 papers). Hélène Karcher collaborates with scholars based in Switzerland, United States and France. Hélène Karcher's co-authors include Mohammad R. K. Mofrad, Roger D. Kamm, Richard Lee, Hayden Huang, Jan Lammerding, Peter J. Mack, Clémentine Nordon, Mikkel Zöllner Ankarfeldt, Hélène Chevrou‐Séverac and Michel Rossignol and has published in prestigious journals such as PLoS ONE, Biophysical Journal and Ophthalmology.

In The Last Decade

Hélène Karcher

40 papers receiving 689 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hélène Karcher Switzerland 14 196 139 127 119 114 44 709
Yvonne M. Mowery United States 20 107 0.5× 295 2.1× 182 1.4× 29 0.2× 248 2.2× 108 1.5k
William J. Hucker United States 20 166 0.8× 80 0.6× 141 1.1× 4 0.0× 257 2.3× 40 1.8k
Beatrice Nardone United States 23 38 0.2× 65 0.5× 72 0.6× 7 0.1× 133 1.2× 78 1.3k
Johannes Alexander Lobrinus Switzerland 19 95 0.5× 97 0.7× 99 0.8× 25 0.2× 256 2.2× 76 1.2k
Yi Pang United States 17 28 0.1× 58 0.4× 18 0.1× 300 2.5× 187 1.6× 67 1.1k
Julia Arciero United States 16 136 0.7× 90 0.6× 107 0.8× 362 3.0× 190 1.7× 47 1.0k
Yohei Hashimoto Japan 17 30 0.2× 50 0.4× 58 0.5× 389 3.3× 199 1.7× 111 863
Fei Yu China 16 12 0.1× 156 1.1× 73 0.6× 112 0.9× 284 2.5× 64 968
Kung-Ming Jan United States 17 62 0.3× 419 3.0× 231 1.8× 13 0.1× 209 1.8× 36 1.0k
Xiang Ji China 13 21 0.1× 74 0.5× 54 0.4× 28 0.2× 219 1.9× 52 652

Countries citing papers authored by Hélène Karcher

Since Specialization
Citations

This map shows the geographic impact of Hélène Karcher's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hélène Karcher with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hélène Karcher more than expected).

Fields of papers citing papers by Hélène Karcher

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hélène Karcher. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hélène Karcher. The network helps show where Hélène Karcher may publish in the future.

Co-authorship network of co-authors of Hélène Karcher

This figure shows the co-authorship network connecting the top 25 collaborators of Hélène Karcher. A scholar is included among the top collaborators of Hélène Karcher based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hélène Karcher. Hélène Karcher is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Krishnan, Jamuna K., Gerard J. Criner, Fernando J. Martínez, et al.. (2025). Disease Onset and Burden in Patients With Chronic Bronchitis and COPD: A Real-World Evidence Study. Chronic Obstructive Pulmonary Diseases Journal of the COPD Foundation. 12(2). 127–136. 1 indexed citations
3.
Krishnan, Jamuna K., et al.. (2024). Multimorbidities in COPD are Associated With Increased Exacerbations and Health Care Resource Utilization in Real-World Patients from a U.S. Database. Chronic Obstructive Pulmonary Diseases Journal of the COPD Foundation. 11(5). 472–481. 4 indexed citations
4.
Bakri, Sophie J., Marie‐Noëlle Delyfer, Jakob Grauslund, Steffen Andersen, & Hélène Karcher. (2023). Real-World Persistence and Treatment Interval in Patients with Diabetic Macular Edema Treated with Anti-Vascular Endothelial Growth Factors in the USA. Ophthalmology and Therapy. 12(5). 2465–2477. 6 indexed citations
5.
Wykoff, Charles C., Hidetaka Matsumoto, Mark Barakat, et al.. (2023). RETINAL VASCULITIS OR VASCULAR OCCLUSION AFTER BROLUCIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina. 43(7). 1051–1063. 21 indexed citations
6.
Miller, David, et al.. (2023). Real-World Frequency and Management of Ocular Adverse Events in Eyes with Neovascular Age-Related Macular Degeneration Treated with Brolucizumab. Ophthalmology and Therapy. 12(5). 2397–2408. 4 indexed citations
7.
Coney, Joseph, Thomas D. Hull, David Miller, et al.. (2023). One-Year and 18-Month Outcomes in nAMD Patient Eyes Switched to Brolucizumab Alone versus to Brolucizumab Alternating with Other Anti-VEGF Agents. Clinical ophthalmology. Volume 17. 3601–3611. 1 indexed citations
8.
MacCumber, Mathew W., et al.. (2023). One-Year Brolucizumab Outcomes in Neovascular Age-Related Macular Degeneration from a Large United States Cohort in the IRIS® Registry. Ophthalmology. 130(9). 937–946. 8 indexed citations
9.
10.
Coney, Joseph, David Miller, Michael Novák, et al.. (2023). Switching to brolucizumab: injection intervals and visual, anatomical and safety outcomes at 12 and 18 months in real-world eyes with neovascular age-related macular degeneration. International Journal of Retina and Vitreous. 9(1). 8–8. 11 indexed citations
11.
MacCumber, Mathew W., et al.. (2023). Factors Linked to Injection Interval Extension in Eyes with Wet Age-Related Macular Degeneration Switched to Brolucizumab. Ophthalmology. 130(8). 795–803. 5 indexed citations
12.
Liegl, Raffael, et al.. (2022). The Treatment Patterns with Brolucizumab in Germany (REALIZE) Study: A Retrospective Cohort Study Based on Longitudinal Prescription Data. Ophthalmology and Therapy. 12(1). 195–208. 8 indexed citations
13.
Bakri, Sophie J., Hélène Karcher, Steffen Andersen, & Eric H. Souied. (2022). Anti–Vascular Endothelial Growth Factor Treatment Discontinuation and Interval in Neovascular Age-Related Macular Degeneration in the United States. American Journal of Ophthalmology. 242. 189–196. 12 indexed citations
14.
Nordon, Clémentine, et al.. (2019). Ethical and social implications of using predictive modeling for Alzheimer’s disease prevention: a systematic literature review protocol. BMJ Open. 9(3). e026468–e026468. 4 indexed citations
15.
Amzal, Billy, et al.. (2018). PHP42 - EARLY ACCESS PROGRAMS: A COMPARISON BETWEEN FRANCE, GERMANY AND THE UNITED KINGDOM. Value in Health. 21. S157–S157.
16.
Karcher, Hélène, Shuai Fu, Jie Meng, et al.. (2018). The “RCT augmentation”: a novel simulation method to add patient heterogeneity into phase III trials. BMC Medical Research Methodology. 18(1). 75–75. 2 indexed citations
17.
18.
Nordon, Clémentine, Mark Belger, Javier Jiménez, et al.. (2017). Trial exclusion criteria and their impact on the estimation of antipsychotic drugs effect: A case study using the SOHO database. Schizophrenia Research. 193. 146–153. 7 indexed citations
19.
Karcher, Hélène, et al.. (2015). A Practical Guide To Adding Patient Heterogeneity Into Phase Iii Trials: Results from Imi Getreal Wp2. Value in Health. 18(7). A727–A727. 1 indexed citations
20.
Nordon, Clémentine, Hélène Karcher, Rolf H. H. Groenwold, et al.. (2015). The “Efficacy-Effectiveness Gap”: Historical Background and Current Conceptualization. Value in Health. 19(1). 75–81. 111 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yvonne M. Mowery Breakdown of academic impact, for papers by William J. Hucker Breakdown of academic impact, for papers by Beatrice Nardone Breakdown of academic impact, for papers by Johannes Alexander Lobrinus Breakdown of academic impact, for papers by Yi Pang Breakdown of academic impact, for papers by Julia Arciero Breakdown of academic impact, for papers by Yohei Hashimoto Breakdown of academic impact, for papers by Fei Yu Breakdown of academic impact, for papers by Kung-Ming Jan Breakdown of academic impact, for papers by Xiang Ji
Rankless by CCL
2026